Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in acute generalized pustular psoriasis flare
NCT03782792Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by Boehringer Ingelheim. Started Jan 2019; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT03782792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782792.